Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells
- Authors:
- Published online on: March 21, 2013 https://doi.org/10.3892/br.2013.85
- Pages: 399-404
Abstract
Introduction
Receptor tyrosine kinases (RTKs) are cell surface receptors with a high-affinity for growth hormones/factors and which bind the majority of identified tyrosine kinases of cells. RTKs commonly consist of a single subunit with three domains: an extracellular N-terminal, a single hydrophobic transmembrane-spanning and an intracellular C-terminal region. The intracellular C-terminal region contains a tyrosine kinase domain and a segment with multiple tyrosine sites for auto-phosphorylation. This component of RTKs exhibits the highest level of conservation and comprises catalytic domains responsible for the kinase activity of these receptors, which catalyses the tyrosine phosphorylation of RTKs as well as of their substrates. Ligand binding to the extracellular domain of RTKs induces a series of events including the formation of receptor dimers, activation of the tyrosine kinase, tyrosine phosphorylation of the receptor or the substrate of the kinase and consequent signaling (1–4).
RTKs have been shown to be key regulators of normal cell processes and to play a crucial role in the development and progression of various types of cancer. There are >10 classes of RTKs, of which the most intensively studied are: i) the epidermal growth factor receptor (EGFR) class: EGFR class has four structurally related RTKs designated as ErbB-1 through ErbB-4. Among these, ErbB-1 (EGFR) and ErbB-2 are found in numerous human cancers and their excessive signaling may be critical in tumor development and their malignant potential (5); ii) the vascular endothelial growth factor receptor (VEGFR) class: this RTK class is one of the main inducers of endothelial cell proliferation and permeability of blood vessels. VEGFR-1 and VEGFR-2 are the main members of this class (6). VEGFR-2 appears to mediate almost all the known cell responses to VEGF and accumulating data have shown that this kinase was closely associated with the metastasis of tumor cells by accelerating neovascularization (7); iii) the platelet-derived growth factor receptor (PDGFR) class: PDGFs and their cognate tyrosine kinase receptors are involved in multiple tumor-associated processes, including the autocrine growth stimulation of tumor cells, stimulation of tumor angiogenesis and recruitment and regulation of tumor fibroblasts (8); iv) the insulin-like growth factor-1 receptor class (IGF-1R): RTKs in this class stimulate growth in several different cell types, inhibit apoptosis, act as an intermediate in numerous growth hormone responses and stimulate the growth of certain types of cancer, including breast, prostate and lung cancer (9,10). Since RTKs are closely associated with the biological activities of tumor cells, a wide range of inhibitory effects of RTK activation is likely to be of significance in tumor suppression.
Type II cGMP-dependent protein kinase (PKG II) is a serine-threonine kinase that is important in the regulation of cell proliferation and apoptosis (11–14). Of note, accumulating evidence has demonstrated that PKG II is a potential tumor suppressor. Swartling et al(15) reported that PKG II inhibited the proliferation of human neuroglioma cells and this inhibition was associated with a decrease of the expression of transcription factor Sox9 and the phosphorylation of Akt. Wang et al(16) reported that PKG II regulated cell proliferation and differentiation in the colonic mucosa and suppressed the growth of colon cancer cells. Research data from our laboratory demonstrated that the expression and activity of PKG II in human gastric cancer cell lines was significantly lower compared to that of normal cells (17) and the increase of expression and activity of PKG II inhibited the proliferation of gastric cancer cell lines (18). Furthermore, we observed that PKG II inhibited EGF-induced signal transduction of several pathways by inhibiting the activation of EGFR (19,20). Since RTKs share a high conservation in their structure and the kinase phosphorylating site-analyzing software predicted potential serine/threonine phosphorylation sites on certain RTKs, we hypothesized that PKG II may exert a similar inhibitory effect on the activation of other members of the RTK family. This study was designed to investigate the inhibitory effect of PKG II on the phosphorylation/activation of the VEGFR, PDGFR and IGF-1R classes of RTKs.
Materials and methods
Cell lines and reagents
The AGS human gastric cancer cell line was purchased from ATCC (ATCC® no: CRL-1793TM). Adenoviral vectors encoding β-galactosidase (Ad-LacZ) and PKG II (Ad-PKG II) were kind gifts from Dr Gerry Boss and Dr Renate Pilz, University of California, San Diego, USA. Dulbecco's Modified Eagle's Media (DMEM) and fetal calf serum (FCS) were purchased from Gibco (Grand Island, NY, USA). The antibody anti-PKG II was purchased from Abgent Biotechnology (San Diego, CA, USA). Goat anti-β-actin and mouse anti-p-ERK antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Rabbit anti-ERK antibody was obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Rabbit anti-p-VEGFR2, rabbit anti-VEGFR2, rabbit anti-p-PDGFRβ, rabbit anti-PDGFRβ, rabbit anti-p-IGF-1R, rabbit anti-IGF-1R, rabbit anti-p-PI3K p85 and rabbit anti-PI3K p85 antibodies were purchased from Bioworld Technology (St. Louis Park, MN, USA). The horseradish peroxidase-conjugated secondary antibodies were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). The cellular permeable cGMP analog 8-pCPT-cGMP was obtained from Calbiochem (San Diego, CA, USA). Recombinant human VEGF-C, PDGF-BB and IGF-1 were obtained from Peprotech (Princeton, NJ, USA). Electrochemiluminescence (ECL) reagents were obtained from Millipore (Billerica, MA, USA). Other reagents used were of analytical grade.
Preparation of adenoviral vectors
293A cells were transfected with adenoviral vector encoding cDNA of LacZ and PKG II and cultured for up to 10 days until CPE was detected. The cells and culture medium were collected and underwent three freezing-thawing cycles. The supernatants containing the adenoviruses (Ad-LacZ and Ad-PKG II) were used to infect new 293A cells to amplify adenoviruses. Amplified adenoviral preparations were titrated and the pfu/ml was determined and maintained at −80°C until use.
Cell culture and infection with adenoviral vectors
AGS cells were cultured in DMEM supplemented with 10% FCS and maintained at 37°C in a humidified incubator with 95% air and 5% CO2. The medium was changed every two days and the cells were sub-cultured at confluence. On the day prior to infection, cells were freshly planted at 70–80% confluence and transinfection was performed with a multiplicity of infection (MOI) of 100%.
Western blot analysis
Proteins extracted from whole-cell lysates were separated by 10% SDS-PAGE and were transferred onto the PVDF membrane. The primary antibodies were incubated overnight at 4°C and incubated with the corresponding secondary antibodies for 1 h at RT, with three washes following each incubation. ECL reagents were used to demonstrate the positive bands on the membrane.
Prediction of PKG II-specific serine/threonine phosphorylation sites on RTKs
Protein phosphorylation site program GPS2.0 was used to indicate the potential PKG II-specific Ser/Thr phosphorylation site on the RTKs. The results demonstrated that the RTKs investigated in this study possessed potential serine/threonine phosphorylation sites. This observation suggested that PKG II affects the activation of these RTKs by phosphorylating specific Ser/Thr site on the receptors (Table I).
Results
PKG II inhibits the activation of VEGFR
Two membrane receptors exhibited a high affinity for VEGF: VEGF-R1 and VEGF-R2. In response to VEGF binding, VEGF-R2 underwent auto-phosphorylation on multiple tyrosine residues including Tyr 951, 996, 1054 and 1059. Since the phosphorylated sites were involved in the regulation of kinase activity, the phosphorylation of these sites represented the activation of VEGF-R2. In this experiment, western blot analysis with anti-phospho-VEGFR2 (Tyr 951) antibody was used to detect the phosphorylation/activation of VEGF-R2. AGS cells were infected with adenoviral vector encoding LacZ or PKG II overnight, treated with 8-pCPT-cGMP for 1 h and then with 100 ng/ml VEGF-C for 5 min. The cell lysate was subjected to western blot analysis. The result demonstrated that VEGF treatment led to a clear increase of Tyr 951 phosphorylation on VEGFR2, while PKG II effectively prevented the phosphorylation (Fig. 1).
PKG II inhibits the activation of PDGFR
The PDGF molecule consists of two amino acid chains that dimerize to form PDGF-AA, PDGF-AB and PDGF-BB. These functionally distinct isoforms may bind to the receptors PDGFRα and PDGFRβ, leading to their phosphorylation. We performed western blot analysis with antibody against p-PDGFRβ (Tyr 751) to detect the activating effect of PDGF-BB on PDGFRβ and the inhibitory effect of PKG II on this action. AGS cells were treated as described above and western blot analysis with anti p-PDGFRβ (Tyr 751) was performed. The results demonstrated that stimulating with PDGF-BB (100 ng/ml) for 5 min led to a significant increase of Tyr 751 phosphorylation on PDGFRβ. Pre-infection with Ad-PKG II and treatment with 8-pCPT-cGMP effectively inhibited the phosphorylation/activation of PDGFRβ induced by PDGF-BB (Fig. 2).
PKG II inhibits the activation of IGF-1R
There are two types of IGF receptors based on their relative affinities, IGF-1 and IGF-2. IGF-1 receptor (IGF-1R) consists of two α subunits and two β subunits and is therefore preferred over IGF-2. In response to ligand binding, the α chain induces tyrosine autophosphorylation of the β chain. This event triggers a cascade of intracellular signaling. Thus, the tyrosine phosphorylation of the β subunit represents the activation of IGF-1R. In this experiment, AGS cells were infected with Ad-PKG II, treated with 8-pCPT-cGMP and stimulated with IGF-1 (100 ng/ml) respectively as described above. Western blot analysis with antibody against Tyr 1161 phosphorylated IGF-1R was employed to investigate the inhibitory effect of PKG II on the IGF-1-induced activation of IGF-1R. The results showed that IGF-1 treatment caused Tyr 1161 phosphorylation on IGF-1R and PKG II prevented the process (Fig. 3).
PKG II inhibits the ERK activation induced by VEGF, PDGF and IGF-1
Activation of RTK initiates several signal transduction pathways. Of these the MAPK/ERK-mediated pathway is the one closely associated with cell proliferation and differentiation. Tyrosine phosphorylated RTKs are able to recruit the adaptor protein to phosphorylated sites and trigger a serine/threonine kinase cascade to phosphorylate ERK. Phosphorylation at Thr185 and 204 is required for the activation of ERK. Studies have shown that VEGF, PDGF and IGF are able to induce the activation of MAPK/ERK (21,22). In this experiment, western blot analysis with anti phospho-ERK antibody was employed to detect the activation of this signal component induced by VEGF, PDGF and IGF-1 and the inhibition of PKG II on this activation. The results showed that 100 ng/ml of VEGF-C, PDGF-BB and IGF-1 caused phosphorylation/activation of ERK and PKG II prevented their phosphorylation/activation (Fig. 4).
PKG II inhibits the activation of PI3K induced by VEGF, PDGF and IGF-1
The PI3K-mediated pathway is another signal transduction pathway that can be activated by tyrosine kinase receptors and is responsible for the production of lipids with biological activity. PI3Ks are composed of a catalytic (p110) and a regulatory subunit. Various isoforms of the catalytic subunit (p110α, p110β, p110γ and p110δ) have been isolated. p85α and p85β are the regulatory subunits that associate with p110α, p110β and p110δ. Upstream signaling causes the phosphorylation of p85 subunit of PI3K. In this experiment, western blot analysis with anti p85 (Tyr 458) antibody was applied to detect the phosphorylation of p85 induced by VEGF, PDGF and IGF-1 and the inhibition of PKG II on this process. The results showed that treatment with 100 ng/ml of VEGF-C, PDGF-BB and IGF-1 caused an increase of Tyr 458 phosphorylation of p85 and PKG II inhibited the phosphorylation processes (Fig. 5).
Discussion
RTKs are crucial in the regulation of critical cell processes, including proliferation and differentiation, cell survival and metabolism, cell migration and cell-cycle control. Numerous diseases result from genetic changes or abnormalities that alter the activity, abundance, cell distribution or regulation of RTKs. Mutations in RTKs and aberrant activation of their intracellular signaling pathways have been associated with various diseases such as diabetes, inflammation, severe bone disorders, arteriosclerosis and angiogenesis, particularly with regard to cancer (3). Therefore, inhibiting the activation/activity of these RTKs is crucial in tumor suppression.
EGFR exists on the cell surface. Overexpression and mutation of EGFR often occurs in most cancers (23) and patients with overexpression of EGFR usually have a poor prognosis (24). The activating process of EGFR includes the phosphorylation of its intracellular domain and different phosphorylation sites are associated with different signal pathways. For example, phosphorylation of Tyr 1068 and 1086 on EGFR is associated with the MAPK/ERK-mediated pathway (25). Previously, we showed that PKG II inhibits the EGF-induced activation of the key signal transduction components in the MAPK/ERK-mediated pathway and inhibits the phosphorylation/activation of EGFR induced by EGF (19,20), revealing that PKG II exerts an inhibitory effect on TK activity of EGFR and the consequent inhibition of EGF/EGFR-mediated signal transductions.
The VEGF family comprises the members VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, PLGF-1 and PLGF-2. These members are important signaling proteins involved in tumor growth and angiogenesis. The main receptors, VEGFR1 and VEGFR2, are responders of VEGFs. VEGF binds mainly with VEGFR2 and the receptor exhibits robust protein-tyrosine kinase activity in response to its ligands and is the predominant mediator of VEGF-stimulated endothelial cell migration, proliferation, survival and enhanced vascular permeability (26). A previous study has shown that VEGF expression in gastric cancer was increased and was associated with an increase of blood vessel density and invasion as well as metastasis of lymph node, bone marrow and other tissues (27). When VEGF binds with VEGFR2, it induces the dimerization of VEGFR2 that leads to autophosphorylation and activation of the receptor. Major phosphorylation sites on VEGFR2 include Tyr 951, 1054, 1059, 1175 and 1214 (28). Our results showed that in AGS cells, VEGF-C induced the phosphorylation of Tyr 951 on VEGFR2 and PKG II inhibited the phosphorylation process. This suggests that PKG II is able to inhibit the activation of other RTKs, with the exception of EGFR.
PDGFs consist of the amino acid chains, A and B, which dimerize to form the isoforms PDGF-AA, PDGF-AB and PDGF-BB. Of these, PDGF-BB stimulates cells to enter the G1-S phase and proliferate (29). The PDGFR family consists of PDGFRα and PDGFRβ and previous studies (30–33) have shown that PDGFR expression increased in several cancers including liver, pancreatic, colon and gastric cancer. Similar to the activation of EGFR and VEGFR, the activation of PDGFR by PDGFs includes the binding of PDGFs with the extracellular domain of the receptor, with the consequent phosphorylation of intracellular domains of the receptor and Tyr 751 being one of the phosphorylation sites (34). Our results have demonstrated that in the AGS gastric cancer cell line, PDGF-BB induced the phosphorylation of Tyr 751 on PDGFRβ and PKG II inhibited the phosphorylation process, providing further evidence to identify PKG II as a cancer inhibitor by suppressing the activation of RTKs.
IGFR is a tetramer comprising α and two β chains. The intracellular part of β chains has tyrosine kinase activity. IGF-1 and -2 are capable of binding with α chains and cause activation of the kinase. The phosphorylation of Tyr 1161 on the receptor is an important event for the activation (35). We assessed anti-phospho-IGF-1R (Tyr 1161) to detect the phosphorylation/activation of IGF-1R and observed that in AGS cells, PKG II inhibited the activating effect of IGF-1R on its receptor. Findings of a previous study showed that IGF-1R is widely expressed in cancer tissues, including renal, colon and gastric cancer (11). In cancer cells, IGF-1R is able to inhibit apoptosis, stimulate vasculogenesis and angiogenesis, regulate migration and promote cell adherence (36). IGF-1R has become a crucial target gene in cancer therapy. Our results showed that PKG II inhibited the activation of IGF-1R, confirming the potential cancer inhibitory effect of this protein kinase by inhibiting RTK activity as well as indicating that PKG II inhibits the activation of RTK with structure difference (a tetramer but not dimer).
In conclusion, our results have demonstrated that PKG II exerts an inhibitory effect on the activation of key RTK members. This suggests that PKG II exerts wide range inhibition on tumor cells. However, more studies are required to confirm this kinase as a potential tumor suppressor.
Acknowledgements
This study was supported by the National Natural Science Foundation of China (nos. 81272755, 31040002 and 81201959); The Innovation Grant of Jiangsu University.
References
|
Robinson DR, Wu YM and Lin SF: The protein tyrosine kinase family of the human genome. Oncogene. 19:5548–5557. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Zwick E, Bange J and Ullrich A: Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer. 8:161–173. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Lemmon MA and Schlessinger J: Cell signaling by receptor-tyrosine kinases. Cell. 141:1117–1134. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Choura M and Rebaï A: Receptor tyrosine kinases: from biology to pathology. J Recept Signal Transduct Res. 31:387–394. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Berezov A, Wang Q, et al: ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 117:2051–2058. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Stuttfeld E and Ballmer-Hofer K: Structure and function of VEGF receptors. IUBMB Life. 61:915–922. 2009. View Article : Google Scholar | |
|
Holmes K, Roberts OL, Thomas AM and Cross MJ: Vascular endothelial growth factor receptor-2: structure, function, intra-cellular signalling and therapeutic inhibition. Cell Signal. 19:2003–2012. 2007. View Article : Google Scholar | |
|
Suzuki S, Dobashi Y, Hatakeyama Y, et al: Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer. BMC Cancer. 30:659–668. 2010.PubMed/NCBI | |
|
Hartog H, Wesseling J, Boezen HM and van der Graaf WT: The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer. 43:1895–1904. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ouban A, Muraca P, Yeatman T and Coppola D: Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol. 34:803–808. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Cook AL and Haynes JM: Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal. 16:253–261. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Cook AL and Haynes JM: Phosphorylation of the PKG substrate, vasodilator-stimulated phosphoprotein (VASP), in human cultured prostatic stromal cells. Nitric Oxide. 16:10–17. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chiche JD, Schlutsmeyer SM, Bloch DB, et al: Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. J Biol Chem. 273:34263–34271. 1998. View Article : Google Scholar | |
|
Hood J and Granger HJ: Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells. J Biol Chem. 273:23504–23508. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Swartling FJ, Ferletta M, Kastemar M, et al: Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. Oncogene. 28:3121–3131. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wang R, Kwon IK, Thangaraju M, et al: Type 2 cGMP-dependent protein kinase regulates proliferation and differentiation in the colonic mucosa. Am J Physiol Gastrointest Liver Physiol. 303:G209–G219. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yang SQ, Chen YC, Wang Y, et al: Expression of cGMP dependent protein kinase II in cancer cell lines was obviously decreased. J Jiangsu Univ (Medicine edition). 18:1–5. 2008. | |
|
Chen YC, Ren F, Sang JR, et al: Type II cGMP-dependent protein kinase inhibits proliferation of the gastric cancer cell line BGC-823. Mol Med Rep. 3:361–366. 2010.PubMed/NCBI | |
|
Wu Y, Chen Y, Qu R, et al: Type II cGMP-dependent protein kinase inhibits EGF-triggered signal transduction of the MAPK/ERK-mediated pathway in gastric cancer cells. Oncol Rep. 27:553–558. 2010.PubMed/NCBI | |
|
Lan T, Chen Y, Sang J, et al: Type II cGMP-dependent protein kinase inhibits EGF-induced MAPK/JNK signal transduction in breast cancer cells. Oncol Rep. 27:2039–2044. 2012.PubMed/NCBI | |
|
Fournier NM, Lee B, Banasr M, et al: Vascular endothelial growth factor regulates adult hippocampal cell proliferation through MEK/ERK- and PI3K/Akt-dependent signaling. Neuropharmacology. 63:642–652. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pratsinis H and Kletsas D: PDGF, bFGF and IGF-I stimulate the proliferation of intervertebral disc cells in vitro via the activation of the ERK and Akt signaling pathways. Eur Spine J. 16:1858–1866. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Quatrale AE, Porcelli L, Silvestris N, et al: EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front Biosci. 16:1962–1972. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Normanno N, Bianco C, De Luca A, et al: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 10:1–21. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Oda K, Matsuoka Y, Funahashi A and Kitano H: A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 1:2005.00102005.PubMed/NCBI | |
|
Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23:1011–1127. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gretschel S, Astrosini C, Vieth M, et al: Markers of tumor angiogenesis and tumor cells in bone marrow in gastric cancer patients. Eur J Surg Oncol. 34:642–647. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Koch S and Claesson-Welsh L: Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med. 2:a0065022012. View Article : Google Scholar : PubMed/NCBI | |
|
Heldin CH: Structural and functional studies on platelet-derived growth factor. EMBO J. 11:4251–4259. 1992.PubMed/NCBI | |
|
Li ZF, Su YF and Chen XP: Expression of platelet-derived growth factor receptor in hepatocellular carcinoma and portal vein tumor thrombus. Acta Academiae Medicinae Qingdao Universitatis. 44:307–311. 2008.(In Chinese). | |
|
Luo HG, Ding YW, Ma TX, et al: Study on the correlation between flt-1, bFGFR, PDGFR and tumor biology in pancreatic carcinoma. Zhonghua Xiao Hua Wai Ke Za Zhi. 1:253–255. 2002.(In Chinese). | |
|
Zhu HT, Han J and Ma L: Expression and clinical significance of PDGFRalpha and PDGFRbeta in colorectal cancer. Ai Zheng. 27:654–660. 2008.(In Chinese). | |
|
Liu DC, Li RG, Zhou JP, et al: Relationship between the expression of PDGF and PDGFR and MVC in the gastric carcinoma. Zhongguo Lin Chuang Yi Sheng. 5:1061–1062. 2003.(In Chinese). | |
|
Board R and Jayson GC: Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Updat. 8:75–83. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 16:3–34. 1995.PubMed/NCBI | |
|
Neid M, Datta K, Stephan S, et al: Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. J Biol Chem. 279:3941–3948. 2004. View Article : Google Scholar |
